Session » (0423–0459) RA – Treatments Poster I

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 0423

Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis

Abstract Number: 0424

Real-World Effectiveness of Upadacitinib in Patients with Moderate/Severe Rheumatoid Arthritis: 6-Month Data from the Observational UPHOLD Study

Abstract Number: 0425

Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

Abstract Number: 0426

The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis

Abstract Number: 0427

Molecular Characterization of Biologic and Targeted Synthetic DMARDs Effects Through Ex- vivo Studies in Rheumatoid Arthritis Immune Cells

Abstract Number: 0428

Real World Patterns of Advanced Therapy Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort

Abstract Number: 0429

Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study

Abstract Number: 0430

A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis

Abstract Number: 0431

Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment

Abstract Number: 0432

Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice

Abstract Number: 0433

DMARD Initiation in Older Adults with New Diagnosis of Late-Onset Rheumatoid Arthritis

Abstract Number: 0434

Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-

Abstract Number: 0435

Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following Release of Safety Data

Abstract Number: 0436

Patients with Difficult-to-treat Rheumatoid Arthritis Have Higher Levels of Inflammation on Ultrasound

Abstract Number: 0437

Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis

Abstract Number: 0438

Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review

Abstract Number: 0439

Humoral Immune Response to 13 Valent-conjugate and 23-valent Polysaccharide Pneumococcal Vaccines in RA Patients Treated with Abatacept: Results of the Open Randomized Controlled Trial VACINA (Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients)

Abstract Number: 0440

Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis

Abstract Number: 0441

Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors

Abstract Number: 0442

Infliximab Clearance a Predictive Factor of Pharmacokinetic Origin in Relation to Suboptimal Pharmacokinetics and Immunogenicity in United States Based Rheumatology Practices

Abstract Number: 0443

The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis

Abstract Number: 0444

Safety, Tolerability, and Pharmacokinetics of a Novel Synthetic Disease Modifying Antirheumatic Drug, TCK-276, After Single Ascending Dose in Healthy Subjects and Multiple Ascending Doses in Patients with Rheumatoid Arthritis

Abstract Number: 0445

Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-severe Rheumatoid Arthritis: Results of a Randomized Double-blind Study

Abstract Number: 0446

Review of Rheumatoid Arthritis Treatment Landscape During the COVID-19 Pandemic

Abstract Number: 0447

Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER

Abstract Number: 0448

Cardioprotective Impact of JAKi, Tofacitinib, on CV Risk in Rheumatoid Arthritis: JAKi CV Risk Impact Study

Abstract Number: 0449

Parsing Pathophysiology of Rheumatoid Arthritis-associated Lymphoproliferative Disorders via Whole RNA Transcriptome Analysis: Multi-center Study in Japan

Abstract Number: 0450

Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting

Abstract Number: 0451

Long-term Clinical Profile of Filgotinib in Patients with Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post Hoc Subgroup Analysis

Abstract Number: 0452

Real Life Safety and Survival of Targeted Therapies in Arthritis Patients over Age of 65

Abstract Number: 0453

Risk of Lung Cancer in Veterans with Rheumatoid Arthritis in Relation to Use of Conventional versus Biologic or Targeted Synthetic DMARDs

Abstract Number: 0454

Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices

Abstract Number: 0455

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial

Abstract Number: 0456

The “Topics” in the Electronic Health Record of Rheumatoid Arthritis Patients Before Initiating Targeted Therapies and Association with Future Treatment Course

Abstract Number: 0457

Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival

Abstract Number: 0458

Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience

Abstract Number: 0459

Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.